Moleculin Biotech (NASDAQ:MBRX) Announces Quarterly Earnings Results

Moleculin Biotech (NASDAQ:MBRX) released its earnings results on Thursday. The company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.15, FiscalAI reports.

Moleculin Biotech Stock Performance

MBRX stock traded up $0.05 during midday trading on Thursday, hitting $0.57. 1,322,819 shares of the stock were exchanged, compared to its average volume of 567,823. The stock’s 50-day moving average price is $2.10 and its 200-day moving average price is $2.54. The stock has a market cap of $4.06 million, a price-to-earnings ratio of -0.03 and a beta of 1.83. Moleculin Biotech has a fifty-two week low of $0.16 and a fifty-two week high of $17.23.

Wall Street Analyst Weigh In

MBRX has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Wall Street Zen cut shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $22.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.